These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37710381)

  • 1. Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Nanaa A; He R; Foran JM; Badar T; Gangat N; Pardanani A; Hogan WJ; Litzow MR; Patnaik M; Al-Kali A; Alkhateeb HB
    Br J Haematol; 2024 Jan; 204(1):171-176. PubMed ID: 37710381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
    Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
    Wang N; He J; Liu F
    Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Shimony S; Stone RM; Stahl M
    Curr Opin Hematol; 2022 Mar; 29(2):63-73. PubMed ID: 34966123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
    Mei C; Ye L; Ren Y; Zhou X; Ma L; Xu G; Xu W; Lu C; Yang H; Luo Y; Jiang L; Lang W; Zhu H; Jin J; Tong H
    Hematol Oncol; 2023 Aug; 41(3):546-554. PubMed ID: 36516239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?
    Masetti R; Baccelli F; Leardini D; Locatelli F
    Blood Adv; 2024 Jul; 8(13):3583-3595. PubMed ID: 38701350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with
    Wang X; Xiao Z; Qin T; Xu Z; Jia Y; Qu S; Li B; Pan L; Gao Q; Jiao M; Gale RP
    Hematology; 2024 Dec; 29(1):2338509. PubMed ID: 38597818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
    Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
    Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
    Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Du Y; Li C; Zhao Z; Liu Y; Zhang C; Yan J
    BMC Cancer; 2023 Aug; 23(1):764. PubMed ID: 37592239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.